Butcher Arthur C

Butcher Arthur C, an executive vice president and group president at Boston Scientific (BSX), has maintained a consistent sell-side bias across his 71 reported Form 4 transactions, with roughly $7.0 million in open-market sales and zero open-market purchases. His most significant dispositions occurred on December 1, 2025 ($1.76 million) and August 1, 2025 ($1.81 million), both executed as code "S" transactions. These sales were paired with option exercises (code "M") that generated modest acquisition values—between roughly $17,000 and $188,000 per exercise—indicating a pattern of exercising vested options and immediately liquidating the underlying shares rather than accumulating additional positions. The remainder of Butcher's activity reflects routine compensation mechanics rather than discretionary trading. A series of February 2026 filings show code "A" grants and code "M" exercises with zero dollar values, alongside code "F" tax-withholding sales ranging from $56,895 to $1.88 million. The largest of these, a $1.88 million "F" transaction on February 13, 2026, corresponds to shares withheld to cover tax obligations on vesting equity—an automatic process that does not signal a directional view. His most recent filings, dated June 18, 2026, involve zero-value grants and exercises in STAAR Surgical (STAA), where he also holds a position, though no open-market trades have been reported in that ticker. Across both BSX and STAA, Butcher's Form 4 history shows no recent open-market purchases (code "P") and only two recent sales, both from late 2025. The overall pattern—large periodic sales tied to option exercises, routine tax-withholding events, and equity grants—suggests a compensation-driven cadence rather than concentrated timing around specific price levels. His total acquired value of roughly $519,000, almost entirely from option exercises and an "I" transaction in February 2026, is dwarfed by his $7.0 million in sales, reinforcing a net reduction in direct share ownership over the reporting period.